Olivier Frey's Biography

Olivier Frey, Vice President Technologies and Platforms, InSphero AG

Olivier Frey is Vice President and Head of Technology & Platforms at InSphero and leads the Microphysiological Systems and Organ-on-Chip programs. Before joining InSphero, he was group leader and SNF Ambizione fellow at the Department of Biosystems Science and Engineering of ETH Zurich, Switzerland. He received his Doctoral degree in Micro Engineering from EPF Lausanne, Switzerland, at Laboratory of Prof. Nico de Rooij, and a Diploma in Microtechnology, Mechanics and Economics from ETH Zürich.

Implementing a Scalable Body-on-a-Chip Metabolic Disease Model based on Human Liver and Islet Microtissues

Tuesday, 15 October 2019 at 09:30

Add to Calendar ▼2019-10-15 09:30:002019-10-15 10:30:00Europe/LondonImplementing a Scalable Body-on-a-Chip Metabolic Disease Model based on Human Liver and Islet MicrotissuesOrgan-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Liver and pancreas constitute key organs in the metabolic syndrome and are highly interacting through different endocrine factors to maintain glucose homeostasis in the human body. An impaired function of one of the organs can cause metabolic diseases, such as diabetes or NASH. Studying these diseases requires a systemic model that can reproduce organ-organ-interactions. The practical implementation of human in-vitro multi-tissue systems in a scalable format includes several challenges. Key aspects encompass biological and technical reproducibility, availability of tissue models, possibility of on-demand production, their usability in suitable treatment windows, access to clinically relevant readouts, and system compatibility with standard lab processes. We implemented a human in-vitro multi-tissue system in a scalable format using 3D organotypic microtissues for establishing organ-organ interactions. The liver model consisted of a primary human hepatocyte/Kupffer cell co-culture with preserved metabolic and inflammatory function over at least two weeks. The primary human islet microtissues comprised all pancreatic endocrine cells at physiological ratio and remained glucose responsive over the same culturing period. The different microtissues were assembled in a microfluidic chip using a pipetting robot enabling an adequate number of replicates at minimal operational complexity for compound testing with access to a wide range of readouts.

Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/LondonOrgan-on-a-Chip World Congress 2019Organ-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors